Cost-effectiveness study of atezolizumab vs. durvalumab : real-world data on first-line chemotherapy combined with immune-checkpoint inhibitors for extensive disease small-cell lung cancer

Cost-effectiveness study of atezolizumab vs. durvalumab : real-world data on first-line chemotherapy combined with immune-checkpoint inhibitors for extensive disease small-cell lung cancer - cost effectiveness study of chemocherapy combined with immune checkpoint inhivitors for extensive disease small cell lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053483

Enrollment

200

Registered

2024-01-30

Start date

2023-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

extensive disease small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Extensive small cell lung cancer or localized small cell lung cancer that has recurred after surgery or radiation (2) Atezolizumab combination therapy (CBDCA + ETP + Atezolizumab) or Durvalumab combination therapy (CDDP/CBDCA + ETP + Durvalumab) Treatment was started by December 31st in 2022

Exclusion criteria

Exclusion criteria: Cases judged by researchers at each institution to be inappropriate for registration.

Design outcomes

Primary

Measure	Time frame
cost effectiveness	—

Countries

Japan

Contacts

Public ContactKatsuya Hirano

Kobe Minimally Invasive Cancer Center Division of Thoracic Oncology

tkp_henyas@yahoo.co.jp0783044100

Outcome results